Pivonello, R. http://orcid.org/0000-0002-9632-1348
Fleseriu, M. http://orcid.org/0000-0001-9284-6289
Newell-Price, J. http://orcid.org/0000-0002-0835-5493
Shimatsu, A. http://orcid.org/0000-0002-9688-006X
Feelders, R. A.
Kadioglu, P. http://orcid.org/0000-0002-8329-140X
Tabarin, A.
Brue, T. C. http://orcid.org/0000-0001-8482-6691
Geer, E. B. http://orcid.org/0000-0003-3722-1889
Piacentini, A.
Pedroncelli, A. M.
Biller, B. M. K. http://orcid.org/0000-0003-4359-4622
Clinical trials referenced in this document:
Documents that mention this clinical trial
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease
https://doi.org/10.1007/s40618-024-02359-6
Funding for this research was provided by:
Novartis Pharma AG
Recordati AG
Università degli Studi di Napoli Federico II
Article History
Received: 8 June 2023
Accepted: 9 March 2024
First Online: 2 May 2024
Declarations
:
: RP has received research funding from Recordati AG, Corcept Therapeutics, Strongbridge Biopharma, and Neurocrine Biosciences and served as a consultant for Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, and H Lundbeck A/S. MF reports grants to her university and occasional scientific consulting fees from Recordati Rare Diseases, Sparrow, and Xeris (Strongbridge); she served as a member of the LINC 3 steering committee. JNP reports research grants and consultancy payments to his university from Crinetics, Diurnal, HRA Pharma, and Recordati Rare Diseases. AS reports serving as a speaker and consultant for Recordati; he also served as a member of the LINC 3 steering committee. RAF reports research grants from Strongbridge and Corcept Therapeutics and consultancy fees from Recordati Rare Diseases and Corcept Therapeutics. PK has no conflicts of interest to disclose. AT reports research contracts and consulting and conference fees from HRA Pharma, Ipsen-Biotech, Novartis, and Recordati Rare Diseases. TCB reports institutional research support from Sandoz and Pfizer and consultancy and lectureship fees from Novartis, Ipsen, Strongbridge, Pfizer, and Recordati Rare Diseases. EBG reports research grants to her hospital from Xeris (Strongbridge), Recordati Rare Diseases, Sparrow, and Corcept Therapeutics and personal consulting fees from Xeris (Strongbridge). AP is an employee of Recordati. AMP was an employee of Recordati when the analyses were conducted. BMKB reports research grants to her institution from Novartis, Strongbridge, and Millendo and occasional consulting honoraria from HRA Pharma, Novartis, Recordati Rare Diseases, Sparrow, and Xeris (Strongbridge); she served on the LINC 3 steering committee.
: The study was conducted in accordance with the Declaration of Helsinki, with an independent ethics committee/institutional review board at each site approving the study protocol.
: Patients provided written informed consent to participate.